Sanofi: set to acquire Kiadis
(CercleFinance.com) - Sanofi has announced a final agreement by which it will launch a takeover bid (subject to certain usual conditions) on all of Kiadis shares at a price of 5.
45 euros per share, meaning a total valuation of about 308 million euros.
The acquisition will enable Sanofi to add a new generation Natural Killer (K-NK) exclusive cell platform and a portfolio of immunotherapy and cell-based infectious disease treatments.
Subject to the deal's conclusion, Sanofi will provide resources and capacities to accelerate the development of Kiadis programs in blood cancers, solid tumours and infectious diseases, and maximise their potential.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
45 euros per share, meaning a total valuation of about 308 million euros.
The acquisition will enable Sanofi to add a new generation Natural Killer (K-NK) exclusive cell platform and a portfolio of immunotherapy and cell-based infectious disease treatments.
Subject to the deal's conclusion, Sanofi will provide resources and capacities to accelerate the development of Kiadis programs in blood cancers, solid tumours and infectious diseases, and maximise their potential.
Copyright (c) 2020 CercleFinance.com. All rights reserved.